Catatonia is diagnosed by the presence of three or more of the following 12 psychomotor symptoms in association with a mental disorder, medical condition, or unspecified:

stupor: no psycho-motor activity; not actively relating to the environment
catalepsy: passive induction of a posture held against gravity
waxy flexibility: allowing positioning by an examiner and maintaining that position
mutism: no, or very little, verbal response (exclude if known aphasia)
negativism: opposition or no response to instructions or external stimuli
posturing: spontaneous and active maintenance of a posture against gravity
mannerisms that are odd, circumstantial caricatures of normal actions
stereotypy: repetitive, abnormally frequent, non-goal-directed movements
agitation, not influenced by external stimuli
grimacing: keeping a fixed facial expression
echolalia: mimicking anothers speech
echopraxia: mimicking anothers movements.Other disorders (additional code 293.89 [F06.1] to indicate the presence of the co-morbid catatonia):

Catatonia associated with autism spectrum disorder
Catatonia associated with schizophrenia spectrum and other psychotic disorders
Catatonia associated with brief psychotic disorder
Catatonia associated with schizophreniform disorder
Catatonia associated with schizoaffective disorder
Catatonia associated with a substance-induced psychotic disorder
Catatonia associated with bipolar and related disorders
Catatonia associated with major depressive disorder
Catatonic disorder due to another medical conditionIf catatonic symptoms are present but do not form the catatonic syndrome, a medication- or substance-induced aetiology should first be considered.ICD-11 classification
In ICD-11 catatonia is defined as a syndrome of primarily psychomotor disturbances that is characterized by the simultaneous occurrence of several symptoms such as stupor; catalepsy; waxy flexibility; mutism; negativism; posturing; mannerisms; stereotypies; psychomotor agitation; grimacing; echolalia and echopraxia.
Bepotastine (Talion, Bepreve) is a 2nd generation antihistamine. It was approved in Japan for use in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively. It is currently marketed in the United States as an eye drop under the brand-name Bepreve, by ISTA Pharmaceuticals, a subsidiary of Bausch + Lomb. Pharmacology
Bepotastine is available as an ophthalmic solution and oral tablet. It is a direct H1-receptor antagonist that inhibits the release of histamine from mast cells. The ophthalmic formulation has shown minimal systemic absorption, between 1 and 1.5% in healthy adults. Common side effects are eye irritation, headache, unpleasant taste, and nasopharyngitis. The main route of elimination is urinary excretion, 75-90% excreted unchanged. Marketing history
It is marketed in Japan by Tanabe Seiyaku under the brand name Talion. Talion was co-developed by Tanabe Seiyaku and Ube Industries, the latter of which discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju, now owned by Allergan, exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. Senju, in turn, has granted the United States rights for the ophthalmic preparation to ISTA Pharmaceuticals. Sales and patents
In 2011, ISTA pharmaceuticals experienced a 2.4% increase in net revenues from 2010, which was driven by the sales of Bepreve. Their net revenue for 2011 was $160.3 million. ISTA Pharmaceuticals was acquired by Bausch & Lomb in March 2012 for $500 million. Bausch & Lomb hold the patent for bepotastine besilate (https://www.accessdata.fda.gov/scripts/cder/ob/docs/temptn.cfm.